Brief Summary
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colonthe longest portion of the large bowel that absorbs water and salts from ingested food cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs.
Intervention / Treatment
- Biological: Dostarlimab
- Drug: CAPEOX
- Drug: FOLFOX
Inclusion Criteria:
- Has untreated pathologically confirmed colon adenocarcinomacancer arising from mucus-producing glands in organs
- Has resectable colon adenocarcinoma defined as clinically T4N0 or Stage III
- Has radiologically evaluable disease
- Has a tumor demonstrating the presence of either dMMR status or MSI-H